# Er-Kim

> Er-Kim is an independent pharmaceutical commercialization company operating across 49 EMEA markets since 1981. We partner exclusively with growth-stage biotech companies to launch rare disease and specialty medicines across Central and Eastern Europe, South Europe, Eurasia, and the Middle East and North Africa.

## Key facts
- Founded: 1981 in Istanbul by Ahmet Ergun Seval
- Ownership: Independent, family-owned, third generation (Chairman: Mert Zorlular, CEO: Cem Zorlular)
- Markets: 49 across CEE, South Europe, Eurasia, and MENA
- Focus: Rare disease, oncology, specialty medicines, advanced therapies (ATMPs)
- Revenue: EUR 379M (2026 projection)
- Employees: 390 specialists across all disciplines
- Partners: 37+ biotech companies
- Launches: 100+ original molecules since 1981, 30+ orphan medicines
- Speed: 2.4 months average from agreement to first commercial patient access
- Certifications: ISO 9001, ISO 27001, ISO 37001, TRACE, GDP, GVP

## What Er-Kim does
Er-Kim provides end-to-end pharmaceutical commercialization services for biotech companies entering EMEA markets. This includes regulatory affairs, market access and reimbursement, medical affairs, pharmacovigilance, supply chain and logistics (including cryogenic for ATMPs), early access programs, and commercial operations. Er-Kim holds marketing authorizations and operates direct legal entities across its markets — no third-party intermediaries.

## Therapeutic areas
Oncology (14 conditions), Neurology (11 conditions), Hematology (6 conditions), Endocrinology and Metabolic Diseases (7 conditions), Immunology (3 conditions), Dermatology (3 conditions), Nephrology and Cardiology (4 conditions), Pain Sleep and Addiction Medicine (4 conditions), Ophthalmology (1 condition), Advanced Therapies: Gene and Cell (3 conditions)

## Key partners
Ascendis Pharma, Jazz Pharmaceuticals, Immunocore, Alnylam, Apellis, BioCryst, Camurus, Egetis, LEO Pharma, Kyowa Kirin, Krystal Biotech, Orchard Therapeutics, Sentynl Therapeutics, CNX Therapeutics, and others.

## Pages
- [Home](https://www.er-kim.com/): Overview and key metrics
- [The Imperative](https://www.er-kim.com/the-imperative): Why international markets matter for biotech — 45-year track record timeline
- [Offering](https://www.er-kim.com/offering): 16 integrated commercialization functions, 49-market footprint, therapeutic areas, early access programs
- [Impact](https://www.er-kim.com/impact): Partner testimonials and operating metrics
- [Therapeutic Areas](https://www.er-kim.com/therapeutic-areas): 10 therapeutic areas with 65+ conditions
- [Intelligence](https://www.er-kim.com/intelligence): News, press releases, and thought leadership articles
- [Governance](https://www.er-kim.com/governance): Code of ethics, compliance framework, certifications, anti-bribery policy, sanctions compliance, ESG
- [Contact](https://www.er-kim.com/contact): Partnership inquiries and office locations (Athens, Istanbul, Sofia)
- [Careers](https://www.er-kim.com/careers): Open positions and company culture
- [CEO Statement](https://www.er-kim.com/ceo): PharmaVoice 100 Patient Champion 2024 — Cem Zorlular
- [Adverse Events](https://www.er-kim.com/adverse-events): Pharmacovigilance reporting by country
- [Accessibility](https://www.er-kim.com/accessibility): WCAG 2.1 AA conformance statement